Hangzhou Tigermed Consulting Co (FRA:5HZ1) Cyclically Adjusted Revenue per Share: €0.48 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5HZ1 Hangzhou Tigermed Consulting Co Ltd FRA:5HZ1
87 GF Score
Price €4.08
GF Value €5.38
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hangzhou Tigermed Consulting Co Cyclically Adjusted Revenue per Share?

Hangzhou Tigermed Consulting Co FRA:5HZ1 +0.99% 87 Cyclically Adjusted Revenue per Share is €0.48 as of Mar. 2026. GuruFocus rates FRA:5HZ1 with a GF Score™ of 87/100 and a GF Value™ of €5.38 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hangzhou Tigermed Consulting Co's adjusted revenue per share for the three months ended in Mar. 2026 was €0.277. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.48 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Hangzhou Tigermed Consulting Co's average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 21.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hangzhou Tigermed Consulting Co was 25.60% per year. The lowest was 17.50% per year. And the median was 22.90% per year.

As of today (2026-08-03), Hangzhou Tigermed Consulting Co's current stock price is €4.08. Hangzhou Tigermed Consulting Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.48. Hangzhou Tigermed Consulting Co's Cyclically Adjusted PS Ratio of today is 8.50.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hangzhou Tigermed Consulting Co was 90.22. The lowest was 6.82. And the median was 16.50.


Hangzhou Tigermed Consulting Co  (FRA:5HZ1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hangzhou Tigermed Consulting Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.08/0.48
=8.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hangzhou Tigermed Consulting Co was 90.22. The lowest was 6.82. And the median was 16.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hangzhou Tigermed Consulting Co Cyclically Adjusted Revenue per Share Related Terms


Hangzhou Tigermed Consulting Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Hangzhou Tigermed Consulting Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Tigermed Consulting Co Cyclically Adjusted Revenue per Share Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.34 0.39 0.32 0.44

Hangzhou Tigermed Consulting Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.39 0.45 0.44 0.48

FRA:5HZ1 vs TMO, DHR, IDXX: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Cyclically Adjusted PS Ratio falls into.


FRA:5HZ1
87GF Score
Hangzhou Tigermed Consulting Co Ltd FRA:5HZ1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Tigermed Consulting Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hangzhou Tigermed Consulting Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.277/116.3033*116.3033
=0.277

Current CPI (Mar. 2026) = 116.3033.

Hangzhou Tigermed Consulting Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.053 101.400 0.061
201609 0.053 102.400 0.060
201612 0.064 102.600 0.073
201703 0.067 103.200 0.076
201706 0.065 103.100 0.073
201709 0.073 104.100 0.082
201712 0.094 104.500 0.105
201803 0.081 105.300 0.089
201806 0.099 104.900 0.110
201809 0.140 106.600 0.153
201812 0.120 106.500 0.131
201903 0.107 107.700 0.116
201906 0.125 107.700 0.135
201909 0.119 109.800 0.126
201912 0.131 111.200 0.137
202003 0.112 112.300 0.116
202006 0.134 110.400 0.141
202009 0.128 111.700 0.133
202012 0.129 111.500 0.135
202103 0.133 112.662 0.137
202106 0.172 111.769 0.179
202109 0.201 112.215 0.208
202112 0.291 113.108 0.299
202203 0.301 114.335 0.306
202206 0.291 114.558 0.295
202209 0.303 115.339 0.306
202212 0.261 115.116 0.264
202303 0.284 115.116 0.287
202306 0.285 114.558 0.289
202309 0.285 115.339 0.287
202312 0.258 114.781 0.261
202403 0.244 115.227 0.246
202406 0.253 114.781 0.256
202409 0.251 115.785 0.252
202412 0.236 114.893 0.239
202503 0.229 115.116 0.231
202506 0.244 114.907 0.247
202509 0.244 115.471 0.246
202512 0.260 115.832 0.261
202603 0.277 116.303 0.277

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.48 mean?
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a Cyclically Adjusted Revenue per Share of €0.48 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hangzhou Tigermed Consulting Co and its competitors.
Is Hangzhou Tigermed Consulting Co's Cyclically Adjusted Revenue per Share too high?
Hangzhou Tigermed Consulting Co's current Cyclically Adjusted Revenue per Share is €0.48. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's Cyclically Adjusted Revenue per Share compare to TMO and DHR?
Hangzhou Tigermed Consulting Co's Cyclically Adjusted Revenue per Share of €0.48 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Hangzhou Tigermed Consulting Co and its competitors. Hangzhou Tigermed Consulting Co's current Cyclically Adjusted Revenue per Share is €0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.38, compared to a current price of €4.08 — trading 24.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.48. Hangzhou Tigermed Consulting Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current Cyclically Adjusted Revenue per Share is €0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued. The current stock price of €4.08 is trading 24.2% below its estimated GF Value™ of €5.38. GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.

Key valuation signals for FRA:5HZ1:

  • Cyclically Adjusted Revenue per Share: €0.48
  • GF Value™: €5.38 vs. price of €4.08 (24.2% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hangzhou Tigermed Consulting Co Business Description

Other Exchanges 03347:Hong Kong300347:China
Address No. 508 Lujiatan Street, Room 601-610, 6th Floor, Puyan Sub-District, Binjiang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
87GF Score

Get the complete analysis for FRA:5HZ1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.08
Price
€5.38
GF Value